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Abstract
Objective. To quantify the change in quality of life, disease-specific indicators, health and lifestyle before and
during the COVID-19 pandemic among people with musculoskeletal diagnoses and symptoms.
Methods. We undertook an additional follow-up of two existing UK registers involving people with axial spondy-
loarthritis (axSpA) or psoriatic arthritis (PsA) and participants in a trial in the UK who had regional pain and were
identified at high risk of developing chronic widespread pain. Participants completed the study questionnaire
between July and December 2020, throughout which time there were public health restrictions in place.
Results. The number of people taking part in the study was 1054 (596 axSpA, 162 PsA, 296 regional pain). In
comparison with their previous (pre-pandemic) assessment, there was an age-adjusted significant, small decrease
in quality of life measured by EQ-5D [0.020 (95% CI 0.030, 0.009)] overall and across all population groups
examined. This was primarily related to poorer mental health and pain. There was a small increase in fibromyalgia
symptoms, but a small decrease in sleep problems. There was a small deterioration in axSpA disease activity, and
disease-specific quality of life and anxiety in PsA participants. Predictors of poor quality of life were similar pre-
and during the pandemic. The effect of lockdown on activity differed according to age, gender and deprivation.
Conclusion. Important lessons include focusing on addressing anxiety and providing enhanced support for self-
management in the absence of normal health care being available, and awareness that all population groups are
likely to be affected.
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Introduction
The COVID-19 pandemic resulted in unprecedented
changes to the life of people throughout the world dur-
ing 2020. Although specific measures varied according
to country, generally public health measures were put in
place across a very short space of time around March,
to reduce the spread of the virus. In the United
Kingdom, from 23 March 2020 measures were put in
place that confined most people to their home and
Rheumatology key messages
. Lockdown has resulted in decreased self-reported quality of life amongst people with musculoskeletal conditions
and symptoms.
. Deterioration in some disease-specific measures and impacts on health were noted across most population
sub-groups.
. There were negative and positive effects on ability to take physical activity (variable by group).
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meant they were only able to leave for a limited number
of reasons and people identified as ‘vulnerable’ were
advised to ‘shield’ in their home. Subsequent to the na-
tional lockdown, there was a gradual easing of restric-
tions beginning in May 2020, but with a rise in the
number of cases of infection due to COVID-19 at the
end of August 2020 there was then a series of local and
national (specific to England, Scotland, Wales and
Northern Ireland) public health restrictions put in place
which have remained into 2021.
Musculoskeletal health can be supported and main-
tained by physical activity and getting an adequate dur-
ation and quality of sleep. Related to these factors, poor
mental health is an important determinant of reduced
health-related quality of life [1] and a marker for poor
disease outcome in both pain [2, 3] and inflammatory
arthritis [4]. Individuals’ mental health may have been
affected by the amount of time required to be spent at
home and the resulting social isolation, as well as anx-
iety around the pandemic and concerns about health.
Most people in work will have experienced important
changes: some working in stressful circumstances,
others making the transition to home working while
some may either have been furloughed or lost their job.
An interim report of a survey by the Institute of
Employment Studies, involving 500 people working at
home, reported a significant increase in musculoskeletal
complaints [5]. More than half of respondents said they
were exercising less, while around two-thirds reported
loss of sleep due to worry.
While many research studies chose to undertake ad
hoc surveys of convenience samples of people, we
undertook additional follow-ups of well-characterized
groups with musculoskeletal conditions and symptoms.
Future reports from the study will consider impact on
health service usage and experience of healthcare
received, and impact on work. This analysis is focused
on the health of respondents during the public health
restrictions associated with the pandemic and specific-
ally how this had changed since they were previously
surveyed.
Methods
The CONTAIN (COvid-19 aNd musculoskeleTal heAlth
durIng lockdown) study re-surveyed three cohorts of
patients with musculoskeletal disease or symptoms
using a questionnaire comprising existing validated
instruments and questions specific to their experience
during the COVID-19 pandemic. The cohorts were
patients with axial spondyloarthritis (BSRBR-AS) [6],
psoriatic arthritis (BSR-PsA) (protocol: https://osf.io/
jzs8n) and patients with regional musculoskeletal pain
who were at risk of chronic widespread pain and
enrolled in the MAmMOTH randomized controlled trial
[7]. Further details of the study cohorts are given in the
Supplementary text, available at Rheumatology online.
All potential participants received a letter by post (or
an email if details were available) over the period June–
July 2020. Those who received an email but did not re-
spond were then sent a letter by post. The communica-
tion explained about the study and invited recipients to
go online to access the patient information sheet, con-
sent to participate and complete the study question-
naire, which was specific to their cohort. For those
people who wished to participate but were unable to
complete the questionnaire online, we provided email
and telephone contact details to request a mailed ques-
tionnaire. When we were able to do so (from mid-July
2020), these were sent out. Reminder letters were sent
by post from September 2020.
The questionnaire asked about demographic and em-
ployment information, and deprivation was computed
with reference to the population of either Scotland [8],
England [9] or Wales [10], and, along with the classifica-
tion of residence as urban or rural, was determined by
participants’ post codes. Common across all three
cohorts, the questionnaire collected health information
including quality of life (EQ-5D-5L) [11], sleep problems
[12], quantitative measurement of fibromyalgia symp-
toms through the fibromyalgia severity (FS) score from
the 2011 research criteria [13] and questions in relation
to COVID-19. There were also specific questionnaires
for individual cohorts:
BSRBR-AS: quality of life (ASQoL) [14], disease activ-
ity (BASDAI) [15] and function (BASFI) [16]; and
BSR-PsA: quality of life (PsAQoL) [17], depression and
anxiety (PROMIS) [18], and physical activity (IPAQ) [19].
Details of the instruments and scoring is given in the
Supplementary text, available at Rheumatology online.
Ethical approval for CONTAIN was obtained through
applying for substantial amendments to the ethical
approvals for each original study. The ethics approval
for MAmMOTH was from NRES Committee South West
(Cornwall and Plymouth, Reference 16/SW/0019), for
BSRBR-AS from NRES Committee North East (County
Durham and Tees Valley, Reference 11/NE/0374) and for
BSR-PsA from West of Scotland REC 3 (Reference 18/
WS/0126). Informed consent was given by participants.
Patient and patient organization input was obtained in
relation to items asked in the questionnaire and through
review of study documentation.
Analysis
To examine the change in measures from the last survey
time point, mixed effects regression models were used,
with individual participant as a random effect. Only par-
ticipants who had the measure available at each time
point were included in these analyses. For EQ-5D-5L,
the Jenkins Sleep Problem Scale, fibromyalgia severity,
ASQoL, BASDAI, BASFI, PROMIS Anxiety, PROMIS
Depression and PSAQOL, mixed effects linear regres-
sion was used. For changes in the individual items of
the EQ-5D-5L and in IPAQ category, mixed effects or-
dinal logistic regression and mixed effects multinomial
logistic regression were used, respectively. Analyses
were first carried out for the whole sample, then strati-
fied by demographic characteristics and clinical
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characteristics. Analyses were adjusted for age at time
of data collection, and appropriate effect sizes reported
with 95% CIs: mean difference for linear regression,
odds ratios (ORs) for logistic and ordinal logistic regres-
sion, and multinomial odds ratios (MORs) for multinomial
logistic regression. In order to examine for the effects
of non-participation by age, gender, deprivation and
study cohort, a weighted analysis was run with weights
determined by the inverse of the probability of people
in these population sub-groups participating in the
CONTAIN study.
To examine predictors of EQ-5D-5L, two linear regres-
sion models were run, one for pre-pandemic predictors
of pre-pandemic EQ-5D-5L and the other for pre-pan-
demic predictors of current EQ-5D-5L. Regression
coefficients with 95% CIs were reported. To provide an
estimate of the size of the difference in association
between these time points, a mixed effects linear
regression was carried out for each predictor with an
interaction between the predictor and the time point
(previous time point or current survey). The interaction
term is reported with 95% CIs.
The analysis uses the 14 December 2020 version of
the database; all analyses were conducted using Stata
SE 15.1 (StataCorp, College Station, TX, USA).
Results
A total of 1054 people who filled in a study question-
naire were included in the analysis (596 from BSRBR-
AS, 162 from BSR-PsA and 296 from MAmMOTH), rep-
resenting 29% of those invited (27% from BSRBR-AS,
26% from BSR-PsA and 33% from MAmMOTH). Among
the respondents 43% completed the questionnaire in
July 2020, 25% in August–September and 32% in
October–December. The median time since last follow-
up was 1002 days for BSRBR-AS participants,
249.5 days for BSR-PsA and 635 days for MAmMOTH.
Overall, the median age of participants was 59 years
(inter-quartile range: 47–69 years), 55% were male, while
50% reported that they were in full- or part-time work
and 34% were retired. Thirty per cent of the sample
were (based on their postcode) resident in an area clas-
sified as rural while the sample over-represented those
with low levels of deprivation (58% were in the lowest
two quintiles of deprivation). Of the 523 respondents
who reported that they were in paid employment, 205
identified themselves as a ‘key worker’, while a total of
390 (37%) respondents indicated that they had been
advised to shield. Only 1.6% of respondents stated that
they had had COVID-19, a further 8.4% reported that
they had had COVID-19-related symptoms and 10.1%
were unsure if they had had COVID-19-related symp-
toms; the vast majority of respondents (75.2%) reported
that they had not had COVID-19-related symptoms.
In comparison with the previous assessment, there
was an age-adjusted significant decrease in quality of
life [EQ-5D-5L age-adjusted mean difference (MD)
0.020 (95% CI: 0.030, 0.009)]. This was noted
across all age groups, among males and females, and
across all levels of deprivation, time periods of comple-
tion and work status, although not all were statistically
significant (Table 1). Analysis of the individual compo-
nents of EQ-5D-5L demonstrated different effects
across domains. There was no difference in relationship
to mobility and self-care but, after age-adjustment,
respondents were significantly more likely to report
higher levels of pain/discomfort and anxiety/depression
in comparison with the previous follow-up [age-adjusted
OR 1.63 (95% CI: 1.35, 1.96) and 1.79 (95% CI: 1.46,
2.18), respectively] (Table 2). Over all respondents there
was a worsening of fibromyalgia severity score [age-
adjusted MD 0.42 (95% CI: 0.18–0.66)], and this worsen-
ing was noted in both males and females, among those
resident in areas of low and high deprivation, with the
largest change in the early period of follow-up (Table 3).
In contrast there was a small but significant reduction in
sleep problems over all respondents [age-adjusted MD
0.52 (95% CI: 0.81, 0.22)]. This was noted in both
males and females, across all age groups, deprivation
categories, study cohort and time period of completion
(Table 4).
In the two disease cohorts, we examined additional
disease-specific measures as follows.
Axial spondyloarthritis
There were no consistent or important age-adjusted
differences in terms of disease-specific quality of life (as
measured by ASQoL) [age-adjusted MD 0.02 (95% CI:
0.28, 0.33)]. There was also no consistent changes in
population sub-groups although it was noted that there
was relative improvement of disease-specific quality of
life over the period of the study (Table 5A). Disease
activity increased by a small amount [BASDAI age-
adjusted MD 0.13 (95% CI: 0.03, 0.29)], with the larg-
est increase in those resident in areas with the highest
levels of deprivation [0.31 (95% CI: 0.09, 0.71)] and in
those followed up at the earliest time point [0.23 (95%
CI: 0.01, 0.46)], although only the latter was statistically
significant (Supplementary Table A, available at
Rheumatology online). There were no important changes
in function [BASFI age-adjusted MD 0.05 (95% CI:
0.19, 0.09)] overall or in any population sub-group
(Supplementary Table B, available at Rheumatology
online).
Psoriatic arthritis
There was a significant worsening of quality of life, as
measured by the PsAQoL, with an age-adjusted mean
difference of 0.75 (95% CI: 0.19, 1.30); the worsening
was mainly observed in those who were advised to, and
followed, shielding guidance and those living in urban
settings (Table 5B). There were no important or signifi-
cant changes in depression since the last follow-up
either overall [PROMIS Depression age-adjusted MD 0.7
(95% CI: 0.6, 1.9)] or in population subgroups
(Supplementary Table C, available at Rheumatology
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online). In contrast there was a significant increase in
anxiety overall [PROMIS anxiety age-adjusted MD 1.7
(95% CI: 0.5, 2.9)], with the greatest increases in anxiety
noted in the oldest age group (over 75 years), those resi-
dent in the most affluent areas and in the last follow-up
period (Supplementary Table D, available at
Rheumatology online). Since their previous assessment,
while there was a small increase in the number of partic-
ipants who had low levels of physical activity or were
inactive as assessed by the IPAQ [37% vs 32%,
age-adjusted OR vs moderate activity 1.78 (95% CI:
0.78, 4.11)], there was a much larger (and statistically
significant) increase in the proportion classified as highly
active [31% vs 20%, age-adjusted OR 2.54 (95% CI:
1.14, 5.67)]. In comparison with previous assessments,
high levels of activity were particularly noted in females
[age-adjusted MOR 3.88 (95% CI: 1.17, 12.85)] and low
levels of activity in those resident in areas with the
greatest levels of deprivation [age-adjusted MOR 5.27
(95% CI: 1.27, 21.97)] and in the earliest follow-up
period (Supplementary Table E, available at
Rheumatology online).
Weighted analysis
Taking account of non-participation by age, gender and
deprivation had little effect on the estimates of change.
Specifically, the deterioration in EQ-5D [0.021 (95% CI:
0.035, 0.008)], increase in fibromyalgia severity
[0.38 (95% CI: 0.11, 0.64)] and PROMIS anxiety score
[1.57 (95% CI: 0.20, 2.95)] remained and were of a simi-
lar magnitude, as was the reduction in sleep problems
[0.57 (95% CI: 0.89, 0.25)]. The worsening of dis-
ease activity in patients with axSpA was marginally















All participants 1020 0.684 (0.209) 0.664 (0.219) 0.021 (0.032, 0.009) 0.020 (0.030, 0.009)
Year of birth
1924–1945 125 0.664 (0.221) 0.625 (0.253) 0.039 (0.060, 0.009)
1946–1964 477 0.685 (0.208) 0.668 (0.203) 0.017 (0.033, 0.002)
1965–1980 292 0.693 (0.210) 0.677 (0.221) 0.016 (0.036, 0.004)
1981–2001 126 0.685 (0.199) 0.658 (0.239) 0.026 (0.065, 0.013)
Gender
Female 461 0.695 (0.197) 0.666 (0.200) 0.029 (0.045, 0.012) 0.029 (0.045, 0.013)
Male 557 0.676 (0.218) 0.662 (0.234) 0.014 (0.029, 0.001) 0.013 (0.028, 0.002)
Study cohort
BSRBR-AS 578 0.659 (0.224) 0.652 (0.231) 0.007 (0.023, 0.009) 0.004 (0.021, 0.012)
MAmMOTH 288 0.744 (0.159) 0.701 (0.190) 0.043 (0.059, 0.026) 0.040 (0.057, 0.023)
BSR-PsA 154 0.667 (0.210) 0.639 (0.220) 0.029 (0.054, 0.003) 0.030 (0.056, 0.005)
Deprivation
1 (most deprived) 90 0.578 (0.256) 0.580 (0.262) 0.003 (0.038, 0.043) 0.003 (0.039, 0.044)
2 129 0.642 (0.237) 0.609 (0.254) 0.033 (0.068, 0.001) 0.028 (0.063, 0.007)
3 205 0.687 (0.209) 0.660 (0.220) 0.026 (0.054, 0.001) 0.024 (0.052, 0.004)
4 307 0.702 (0.180) 0.677 (0.210) 0.025 (0.042, 0.007) 0.024 (0.042, 0.006)
5 (least deprived) 289 0.716 (0.195) 0.703 (0.184) 0.013 (0.033, 0.006) 0.014 (0.033, 0.007)
Employment
Full-time 361 0.717 (0.181) 0.707 (0.180) 0.010 (0.029, 0.009) 0.015 (0.034, 0.004)
Part-time 145 0.703 (0.186) 0.679 (0.195) 0.024 (0.050, 0.002) 0.024 (0.050, 0.003)
Retired 356 0.698 (0.192) 0.680 (0.202) 0.018 (0.035, 0.0002) 0.014 (0.032, 0.005)
Other 150 0.555 (0.274) 0.506 (0.288) 0.049 (0.084, 0.015) 0.047 (0.082, 0.011)
Urban/rural
Urban 713 0.678 (0.218) 0.654 (0.227) 0.024 (0.037, 0.011) 0.023 (0.036, 0.009)




337 0.624 (0.228) 0.604 (0.226) 0.021 (0.043, 0.002) 0.021 (0.044, 0.001)
Not advised or
not followed
647 0.718 (0.189) 0.697 (0.209) 0.021 (0.033, 0.008) 0.021 (0.034, 0.008)
Date of completion
July 436 0.698 (0.205) 0.675 (0.199) 0.022 (0.038, 0.007) 0.024 (0.040, 0.009)
Aug–Sep 257 0.662 (0.220) 0.639 (0.245) 0.023 (0.048 , 0.001) 0.022 (0.047, 0.004)
Oct–Dec 327 0.684 (0.203) 0.669 (0.223) 0.015 (0.034 , 0.004) 0.013 (0.032, 0.007)
Values in bold are statistically significant.
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higher and the deterioration was statistically significant
[0.18 (95% CI: 0.01, 0.36)].
Predictors of poor quality of life during the
pandemic
Three analyses in relation to poor quality of life are
reported in Table 6: using pre-pandemic data to pre-
dict pre-pandemic quality of life; using pre-pandemic
and pandemic data to predict pandemic quality of life;
and an analysis looking at the change of strength of
association between a factor and pre-pandemic and
pandemic quality of life. The relationship of factors
with poor quality of life is very similar pre- and during
the pandemic: sleep problems, living in areas with
high levels of deprivation, and low levels of physical
activity (which could be examined only in PsA). In the
mixed effects model (model 3 in Table 6), which
included an interaction term for strength of relation-
ship, the only factor showing a change in relationship
was that being a member of the MAmMOTH cohort
(i.e. being at risk of developing chronic widespread
pain) was associated with relatively poorer quality of
life during the pandemic.
Discussion
There was a small detrimental effect on quality of life for
people with musculoskeletal conditions and symptoms
during the period of public health restrictions in the UK
due to COVID-19. The decrease in quality of life was
principally related to mental health and pain, and in the
cohort for which more detailed information was available
on mental health (participants with PsA), this was specif-
ically related to higher levels of anxiety. Participants with
PsA reported a decrease in disease specific quality of
life while there was an increase in disease activity in
participants with axSpA. Factors influencing poor quality
of life, and their importance, were similar pre- and







OR (95% CI) Age-adjusted
OR (95% CI)
Mobility
No problems 472 (46.0) 487 (47.5) 1.02 (0.84, 1.24) 0.93 (0.76, 1.13)
Slight problems 310 (30.2) 277 (27.0)
Moderate problems 167 (16.3) 176 (17.2)
Severe problems 71 (6.9) 80 (7.8)
Unable to walk 6 (0.6) 6 (0.6)
Self-care
No problems 751 (73.2) 752 (73.3) 1.08 (0.84, 1.39) 1.03 (0.80, 1.33)
Slight problems 184 (17.9) 178 (17.4)
Moderate problems 77 (7.5) 71 (6.9)
Severe problems 10 (1.0) 23 (2.2)
Unable to wash and dress 4 (0.4) 2 (0.2)
Usual activities
No problems 431 (41.9) 452 (44.0) 1.01 (0.84, 1.22) 0.97 (0.80, 1.17)
Slight problems 368 (35.8) 332 (32.3)
Moderate problems 177 (17.2) 176 (17.1)
Severe problems 41 (4.0) 57 (5.5)
Unable to do 11 (1.1) 11 (1.1)
Pain/discomfort
No pain or discomfort 130 (12.7) 96 (9.3) 1.65 (1.37, 1.99) 1.63 (1.35, 1.96)
Slight pain or discomfort 498 (48.4) 464 (45.1)
Moderate pain or discomfort 303 (29.5) 343 (33.4)
Severe pain or discomfort 85 (8.3) 104 (10.1)
Extreme pain or discomfort 12 (1.2) 21 (2.0)
Anxiety/depression
Not anxious or depressed 518 (50.4) 437 (42.6) 1.65 (1.36, 2.00) 1.79 (1.46, 2.18)
Slightly anxious or depressed 332 (32.3) 373 (36.3)
Moderately anxious or
depressed
141 (13.7) 178 (17.3)
Severely anxious or depressed 28 (2.7) 30 (2.9)
Extremely anxious or depressed 8 (0.8) 9 (0.9)
OR: odds ratio. Values in bold are statistically significant.
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during the pandemic. In contrast there were small
improvements in sleep reported overall, while there were
both improvements (in females, and at older ages) and
deterioration (those resident in areas of high deprivation)
in the amount of exercise reported during the
restrictions.
Many studies of ill-health during COVID-19 were
conducted by means of ad hoc internet surveys pro-
moted through social media (e.g. [20, 21]). Although
these can provide useful information [22], it is difficult
for them to assess the magnitude of effects due to re-
call and being highly selective in terms of people par-
ticipating. Our study had the advantage of prospective
collection of information before the COVID-19 pandem-
ic and during restrictions. Nevertheless, the time period
since last follow-up varied considerably between and
within studies. Secondly, the 6 months over which the
study was conducted represented different levels of
restrictions and also varied depending on where partic-
ipants lived. Thus, our data need to be interpreted in
the general context of restrictions over this period.
Thirdly, our patient and patient organization partners
commented to us at the time of designing the survey
that there was a perceived ‘survey fatigue’ among
patients because of the number of internet surveys that
were being conducted during the course of the pan-
demic—and indeed this proved to be the case as par-
ticipation was relatively low and caused us to issue an
(initially unplanned) reminder. This was an issue experi-
enced by others such as Smith et al. [23] who reported
a 19% participation rate among patients registered in
the Norfolk Arthritis Register (NOAR) when approached
















All participants 952 8.55 (5.29) 8.84 (5.08) 0.29 (0.05, 0.52) 0.42 (0.18, 0.66)
Year of birth
1924–1945 116 7.48 (5.01) 8.02 (4.63) 0.53 (0.04, 1.11)
1946–1964 440 8.00 (4.93) 8.49 (4.86) 0.48 (0.15, 0.82)
1965–1980 272 8.83 (5.15) 9.08 (5.16) 0.25 (0.22, 0.72)
1981–2001 124 10.9 (6.35) 10.3 (5.72) 0.56 (1.24, 0.11)
Gender
Female 434 9.32 (5.24) 9.59 (5.17) 0.27 (0.07, 0.61) 0.41 (0.06, 0.75)
Male 516 7.90 (5.26) 8.20 (4.92) 0.30 (0.02, 0.63) 0.41 (0.07, 0.74)
Study cohort
BSRBR-AS 527 9.26 (5.55) 9.09 (5.15) 0.17 (0.50, 0.16) 0.03 (0.37, 0.31)
MAmMOTH 280 6.61 (3.87) 7.66 (4.18) 1.05 (0.69, 1.42) 1.10 (0.73, 1.46)
BSR-PsA 145 9.72 (5.76) 10.19 (5.90) 0.47 (0.17, 1.11) 0.53 (0.12, 1.17)
Deprivation
1 (most deprived) 84 10.55 (6.40) 10.74 (6.10) 0.19 (0.62, 1.01) 0.41 (0.42, 1.25)
2 113 8.95 (5.08) 9.39 (5.11) 0.44 (0.28, 1.16) 0.40 (0.34, 1.13)
3 197 9.29 (5.44) 9.10 (5.05) 0.19 (0.73, 0.34) 0.08 (0.63, 0.46)
4 289 8.12 (5.13) 8.57 (4.86) 0.46 (0.05, 0.86) 0.58 (0.16, 0.99)
5 (least deprived) 269 7.68 (4.83) 8.10 (4.79) 0.42 (0.02, 0.86) 0.59 (0.15, 1.04)
Employment
Full-time 343 8.76 (5.30) 8.64 (4.88) 0.13 (0.53, 0.28) 0.13 (0.29, 0.55)
Part-time 134 8.91 (4.92) 9.32 (4.85) 0.41 (0.22, 1.04) 0.48 (0.17, 1.14)
Retired 331 7.14 (4.73) 7.75 (4.50) 0.61 (0.24, 0.98) 0.61 (0.21, 1.00)
Other 134 11.13 (5.98) 11.62 (6.06) 0.49 (0.16, 1.14) 0.61 (0.05, 1.28)
Urban/Rural
Urban 667 8.64 (5.40) 8.98 (5.26) 0.34 (0.06. 0.62) 0.46 (0.17, 0.74)
Rural 285 8.34 (5.04) 8.50 (4.62) 0.16 (0.27, 0.59) 0.36 (0.08, 0.79)
Shielding
Advised and followed 307 10.12 (5.56) 10.21 (5.14) 0.09 (0.36, 0.54) 0.28 (0.17, 0.74)
Not advised or
not followed
611 7.72 (5.02) 8.11 (4.89) 0.39 (0.11, 0.67) 0.52 (0.24, 0.80)
Date of completion
July 403 7.94 (5.02) 8.53 (4.58) 0.59 (0.25 , 0.94) 0.74 (0.39, 1.09)
Aug–Sep 238 9.77 (5.72) 9.78 (5.87) 0.00 (0.48 , 0.49) 0.17 (0.32, 0.67)
Oct–Dec 311 8.41 (5.16) 8.51 (4.95) 0.11 (0.32 , 0.54) 0.21 (0.22, 0.64)
Values in bold are statistically significant.
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for a COVID-19-related survey. We conducted a
weighted analysis to take account of socio-demo-
graphic factors and reassuringly they showed similar
magnitude of change although with a slightly higher es-
timate for change in BASDAI among participants with
axSpA. Finally, while we generally saw less impact of
lockdown on health over time, it is not possible to dis-
entangle this time period effect from the methodologic-
al issue of people who were most severely affected
responding earlier. Nevertheless, the interpretation of
lessening impact with time is generally supported by
longitudinal surveys conducted in the general popula-
tion, for example on mental health [24]. This also
emphasizes that in interpreting the results from the
current study we are not concluding that the changes
in health were “because of participants” musculoskel-
etal conditions.
There have been several reports about the effect of
COVID-19 on health in the UK population. An additional
sweep of the UK Household Survey in April 2020
showed increased levels of psychological distress (com-
pared with the previous pre-pandemic survey) particular-
ly affecting younger people and women [24]. Poor
mental health is a key factor influencing quality of life
among people with musculoskeletal conditions [1] and
also is an independent predictor of response to therapy
[25]. Therefore the effect of the pandemic on mental
health in patients with musculoskeletal symptoms and
conditions is of relevance to their management, and
addressing increasing levels of anxiety is likely to be key
to maintaining quality of life. An analysis of >12 000
people with inflammatory arthritis in the DANBIO register
in Denmark reported that females, people with comor-
bidities, not working, with lower levels of education, on















All participants 927 9.01 (5.52) 8.39 (4.70) 0.62 (0.91, 0.033) 0.52 (0.81, 0.22)
Year of birth
1924–1945 103 8.08 (5.32) 6.99 (3.92) 1.09 (1.98, 0.20)
1946–1964 424 8.88 (5.58) 8.24 (4.70) 0.64 (1.07, 0.21)
1965–1980 272 9.23 (5.62) 8.94 (4.97) 0.29 (0.81, 0.24)
1981–2001 128 9.68 (5.22) 8.23 (4.47) 0.85 (1.65, 0.05)
Gender
Female 422 9.51 (5.33) 9.03 (4.61) 0.48 (0.91, 0.05) 0.41 (0.84, 0.03)
Male 503 8.58 (5.66) 7.87 (4.72) 0.71 (1.11, 0.32) 0.61 (1.01, 0.21)
Study cohort
BSRBR-AS 528 8.99 (5.83) 8.31 (4.83) 0.68 (1.07, 0.29) 0.53 (0.94, 0.13)
MAmMOTH 264 8.71 (4.96) 8.19 (4.45) 0.53 (1.07, 0.02) 0.49 (1.03, 0.06)
BSR-PsA 135 9.62 (5.34) 9.07 (4.66) 0.55 (1.23, 0.14) 0.50 (1.19, 0.19)
Deprivation
1 (most deprived) 79 10.19 (5.99) 9.05 (5.19) 1.14 (2.24, 0.03) 0.90 (2.02, 0.21)
2 122 9.28 (5.98) 8.30 (4.86) 0.99 (1.84, 0.13) 1.00 (1.86, 0.13)
3 190 9.62 (5.47) 8.96 (4.79) 0.66 (1.27, 0.05) 0.62 (1.24, 0.004)
4 278 8.83 (5.35) 8.23 (4.36) 0.51 (1.04, 0.03) 0.37 (0.91, 0.17)
5 (least deprived) 258 8.25 (5.29) 7.88 (4.73) 0.37 (0.90, 0.16) 0.28 (0.81, 0.26)
Employment
Full-time 332 8.95 (5.49) 8.51 (4.78) 0.45 (0.94, 0.04) 0.40 (0.90, 0.11)
Part-time 135 9.41 (5.41) 8.81 (4.37) 0.60 (1.35, 0.15) 0.49 (1.25, 0.27)
Retired 306 8.04 (5.23) 7.20 (4.14) 0.84 (1.35, 0.34) 0.74 (1.26, 0.21)
Other 139 11.06 (5.85) 10.34 (5.19) 0.72 (1.44, 0.003) 0.64 (1.38, 0.09)
Urban/rural
Urban 646 8.99 (5.68) 8.28 (4.81) 0.71 (1.06, 0.36) 0.62 (0.97, 0.27)




297 9.75 (5.75) 8.99 (4.85) 0.76 (1.26, 0.26) 0.59 (1.09, 0.08)
Not advised or
not followed
595 8.61 (5.37) 8.08 (4.61) 0.53 (0.90, 0.15) 0.46 (0.84, 0.08)
Date of completion
July 395 8.69 (5.52) 8.31 (4.78) 0.38 (0.82, 0.06) 0.22 (0.66, 0.22)
Aug–Sep 234 9.46 (5.47) 8.94 (4.60) 0.52 (1.11, 0.07) 0.42 (1.02, 0.17)
Oct–Nov 298 9.07 (5.57) 8.06 (4.66) 1.01 (1.53, 0.49) 0.99 (1.52, 0.47)
Values in bold are statistically significant.
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biologic treatment and with lower quality of life were
more likely both to be anxious and self-isolate [26].
How do we interpret the magnitude of decrease in
quality of life? There has been debate about whether a
minimal clinically important difference (MCID) is relevant
to EQ-5D and where it has been calculated (for EQ-5D-
3L) in the context of musculoskeletal conditions, esti-
mates vary between 0.03 and 0.54 across 12 studies
[27]. For comparison with the decrease in EQ-5D-5L of
0.02 noted here, in the MAmMOTH trial, the cognitive
behaviour therapy intervention (which was shown to be
highly cost effective) resulted in an improvement of qual-
ity of life (using the EQ-5D-5L) over usual care of roughly
similar magnitude, 0.024 [7]. There have been no esti-
mates of MCID for PsAQoL, but again for context, a
study of 28 patients with PsA followed up after a change
in disease modifying therapy showed an average im-
provement of 2.96 in PsAQoL at 6 months [28], in com-
parison with the worsening here over follow-up of 0.75.
It might have been reasonably expected that there could
have been an increase in fibromyalgia-related
symptoms, particularly given the effect of the pandemic
on mental health, and this indeed was the case. One
particular area of interest in the current analysis is
whether particular population sub-groups’ health was
more affected by the restrictions than others. There is
no consistent evidence across the conditions and
domains of such—worsening of domains have affected
both males and females, people of different ages and
across levels of deprivation. It was of particular note
that the influences on poor quality of life were similar
(and of similar magnitude) both before and during the
pandemic. However, it was noted that the deterioration
in quality of life was greatest among the cohort who had
markers for risk of developing chronic widespread pain.
One surprising result is the lower level (on average) of
sleep problems. The magnitude of change was small but
was noted overall and for all population sub-groups
examined. In an environment of uncertainty and increas-
ing anxiety it might have been expect that there would
be detrimental effects on sleep [29]. However, sleep
problems remained an important influence on quality of















All participants 578 6.26 (5.19) 6.22 (5.16) 0.04 (0.34, 0.25) 0.02 (0.28, 0.33)
Year of birth
1924–1945 57 6.33 (4.99) 6.16 (4.91) 0.18 (0.85, 0.49)
1946–1964 260 6.17 (5.16) 6.11 (5.04) 0.06 (0.47, 0.35)
1965–1980 174 6.04 (5.45) 5.96 (5.33) 0.08 (0.68, 0.52)
1981–2001 87 6.97 (4.86) 7.12 (5.35) 0.16 (0.69, 1.00)
Gender
Female 197 7.16 (5.20) 6.87 (5.15) 0.29 (0.82, 0.24) 0.21 (0.76, 0.34)
Male 380 5.79 (5.13) 5.88 (5.15) 0.09 (0.27, 0.44) 0.10 (0.27, 0.47)
Deprivation
1 (most deprived) 58 8.34 (5.35) 8.45 (5.07) 0.10 (0.79, 1.00) 0.23 (0.69, 1.16)
2 88 7.13 (5.67) 7.46 (5.70) 0.33 (0.48, 1.14) 0.26 (0.57, 1.10)
3 107 6.82 (5.01) 6.19 (4.99) 0.63 (1.42, 0.15) 0.60 (1.41, 0.20)
4 162 5.69 (4.91) 5.71 (4.95) 0.02 (0.46, 0.50) 0.05 (0.46, 0.56)
5 (least deprived) 163 5.27 (4.95) 5.29 (4.91) 0.02 (0.53, 0.58) 0.16 (0.42, 0.73)
Employment
Full-time 226 5.53 (4.81) 5.40 (4.73) 0.13 (0.61, 0.36) 0.20 (0.31, 0.71)
Part-time 86 5.70 (5.19) 6.18 (5.31) 0.48 (0.33, 1.29) 0.54 (0.32, 1.39)
Retired 172 5.84 (4.96) 5.39 (4.80) 0.45 (0.94, 0.04) 0.63 (1.20, 0.5)
Other 91 9.49 (5.44) 9.99 (5.18) 0.49 (0.27, 1.25) 0.59 (0.20, 1.39)
Urban/rural
Urban 423 6.41 (5.20) 6.50 (5.30) 0.09 (0.25, 0.43) 0.13 (0.22, 0.48)
Rural 155 5.86 (5.14) 5.46 (4.69) 0.41 (1.02, 0.20) 0.27 (0.90, 0.37)
Shielding
Advised and followed 219 7.51 (5.26) 7.53 (5.16) 0.01 (0.55, 0.57) 0.16 (0.41, 0.73)
Not advised or
not followed
347 5.45 (5.02) 5.35 (5.03) 0.10 (0.44, 0.24) 0.05 (0.41, 0.31)
Date of completion
Jul 251 6.02 (5.03) 6.36 (5.12) 0.34 (0.12, 0.79) 0.51 (0.04, 0.98)
Aug–Sep 174 6.32 (5.20) 6.21 (5.13) 0.11 (0.61, 0.39) 0.12 (0.65, 0.40)
Oct–Dec 153 6.59 (5.42) 6.00 (5.30) 0.60 (1.19, 0.001) 0.64 (1.26, 0.02)
Values in bold are statistically significant.









niversity of Aberdeen user on 12 O
ctober 2021
life during the pandemic. Positive effects on sleep during
the pandemic have been reported—principally around
duration of sleep and reduced variability of sleep pat-
terns. In a study of almost 3 million users of a smart-
phone app in five metropolitan areas across the
Americas, Europe and Asia, there was an increase in
sleep duration between April 2019 and April 2020 of
22.3 min (95% CI: 21.5–23.1) [30]. In a study of 1021 par-
ticipants in a sleep survey in Argentina who had meas-
urements of sleep made both prior to and during the
pandemic, sleep duration was longer during lockdown;
only 37% did not reach the recommended 7 h of sleep
on weekdays during the pandemic compared with 62%
pre-pandemic. However, there was no difference in sleep
quality pre- and during the pandemic [31]. Retrospective
studies asking people to recall sleep patterns have
tended to find people reporting worsening as opposed to
improvement of sleep during the pandemic (e.g. [32]).
Other ‘benefits’ noted in the results include significant
(positive) changes in the likelihood of respondents being
classified as taking high levels of physical activity com-
pared with previously—particularly for older respondents
and females. However, it is noteworthy that these posi-
tive effects were not uniformly seen; indeed respondents
living in areas with higher levels of deprivation were sig-
nificantly more likely to be classed as having low levels
of physical activity compared with the previous follow-
up. We could not find any other large-scale study of
people with musculoskeletal conditions that had exam-
ined the impact on physical activity during the pandemic.
In summary, this study provides evidence of only a small
average decrease in quality of life reported by people with
musculoskeletal symptoms or diagnoses during restrictions
caused by the COVID-19 pandemic, with the main issues
being pain and anxiety. There was also some deterioration
noted in average disease specific measures, again of small
magnitude, an increase in fibromyalgia-related symptoms
but a small reduction in sleep problems. Changes were not
restricted to particular population groups. The results taken
as a whole are generally reassuring but provide some les-
sons for future similar situations: focusing on addressing
anxiety is important, providing enhanced support for self-
management (including in relation to pain) in the absence of
normal health services being available, and being aware that
all patients regardless of circumstances can be affected.
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All participants 132 6.96 (5.42) 7.63 (5.72) 0.67 (0.11, 1.22) 0.75 (0.19, 1.30)
Year of birth
1924–1945 7 5.86 (2.54) 6.74 (4.42) 0.86 (1.14, 2.85)
1946–1964 59 5.97 (5.32) 6.36 (5.47) 0.39 (0.34, 1.12)
1965–1980 53 7.57 (5.70) 8.68 (6.12) 1.11 (0.15, 2.08)
1981–2001 13 9.62 (5.01) 9.62 (4.75) 0.00 (1.90, 1.90)
Gender
Female 79 7.90 (5.35) 8.70 (5.35) 0.80 (0.02, 1.57) 0.82 (0.04, 1.60)
Male 53 5.57 (5.26) 6.04 (5.92) 0.47 (0.28, 1.22) 0.62 (0.14, 1.38)
Deprivation
1 (most deprived) 16 8.00 (6.10) 9.25 (6.68) 1.25 (0.29, 2.79) 1.33 (0.22, 2.89)
2 15 6.87 (5.07) 7.73 (4.95) 0.87 (0.75, 2.49) 0.75 (0.87, 2.38)
3 34 7.79 (5.79) 7.76 (5.74) 0.03 (1.17, 1.11) 0.08 (1.06, 1.23)
4 29 6.24 (4.91) 6.72 (5.52) 0.48 (0.86, 1.82) 0.49 (0.86, 1.83)
5 (least deprived) 38 6.37 (5.39) 7.47 (5.84) 1.11 (0.26, 1.95) 1.26 (0.40, 2.11)
Urban/rural
Urban 99 6.74 (5.54) 7.69 (5.85) 0.95 (0.32, 1.58) 1.02 (0.39, 1.66)
Rural 33 7.64 (5.07) 7.45 (5.37) 0.18 (1.27, 0.91) 0.07 (1.16, 1.03)
Shielding
Advised and followed 59 8.12 (5.92) 9.29 (6.29) 1.17 (0.28, 2.05) 1.29 (0.40, 2.17)
Not advised or
not followed
68 6.07 (4.88) 6.19 (4.71) 0.12 (0.57, 0.81) 0.18 (0.52, 0.87)
Date of completion
Jul 42 5.48 (4.82) 6.36 (5.63) 0.88 (0.13, 1.89) 0.93 (0.08, 1.94)
Aug–Sep 47 8.06 (5.14) 8.70 (5.33) 0.64 (0.32, 1.59) 0.70 (0.26, 1.66)
Oct–Dec 43 7.21 (6.03) 7.70 (6.08) 0.49 (0.42, 1.40) 0.65 (0.27, 1.57)
Values in bold are statistically significant.
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